Introduction
The relationship between humans and the microorganisms they contain has been the object of much evidence via research. The microbiome, an organic unit that is made up of the skin and the gastrointestinal system located inside the human body as well as one that exists on the outer surface of the body, is the hub of some critical functions like metabolism, defense against pathogens through the immune system, and activation of the immune system. The symbiotic host-associated microbiota also has a two-way interrelation in health and disease in that it can regulate and adapt to changes induced by the host and that it can turn into a 'dysbiotic' (healthy microbiome changes to the one associated with disease) while the host is unwell. In this respect, the research in this field impetus the provision of microbiome-based therapeutics (MBTs) for treating many diseases.
The microbiome is not only a shorthand term for bacterial taxonomy but also refers to the metabolic and functional states of mycobiome (gut fungus) and that of virome indicating gut viruses. MBT uses multiple modalities to shift different components of this dynamic system, such as supplementation with microbial metabolites. SCFAs-delivery (short-chain fatty acids) of defined microbial consortia (for example, more than one microbe living together), fecal microbiota transplantation (FMT), etc. Lastly, the prospect of phage therapy and genetically modified microorganisms for site-specific local treatment remains an alternative therapeutic modality to consider.
What Are the Various Microbiome-Based Therapies for Gastrointestinal Disorders?
-
Probiotics: These are live bacteria that exert a health benefit on their host or human beings when administered in adequate amounts. The most often used strains for probiotic applications are Saccharomyces boulardii, Lactobacillus, and Bifidobacterium. By competing with pathogenic or harmful species present in the gut area, probiotics preserve the health of the digestive tract or gut.
-
Prebiotics: Undigested food supports the maintenance and health of beneficial gut bacteria; hence, this is sometimes called 'prebiotic nutrition.' Some types of oligosaccharides (galactooligosaccharides, fructooligosaccharides, and inulin) are examples of prebiotics. There is currently little evidence supporting the use of prebiotics. The latest studies provide data on the quite positive influence of the fiber psyllium on intestinal barrier function; thus, a strong recommendation with generally moderate-quality evidence can be made for treating symptoms of IBS.
-
Fecal Microbiota Transplantation: This technique works based on fecal microbiota transplantation to replenish gut flora in a patient by infusion of stool from a healthy donor. It recently gained immense attention after its successful applications in treating Clostridium difficile infections that were bad and resistant to standard drugs & therapies. FMT is being studied for C diff and many other conditions, such as the effects on other inflammatory bowel diseases. While most of the clinical investigation studies suggest that FMT can induce remission in ulcerative colitis patients for difficile infection but also for the treatment of GI (gastrointestinal) disorders such as IBD (inflammatory bowel disease) characterized by inflammation of the intestines and IBS (inflammatory bowel syndrome) characterized by abdominal pain and changes in the bowel movement, its variable results have prevented it from being widely adopted as mainstream treatment due to many reasons. Further areas of investigation concern safety considerations, including the real risk of infectious agent transmission or unintentional infection.
-
Diet Interventions: Diet has long been understood as one of the most significant factors shaping and dictating microbiota composition in the gut. Dietary interventions primarily target the composition and metabolic activity of ecosystems of multiple species, referred to as gut microbiota. These open a wide avenue for developing functional foods consisting of fuels or compounds available for growth/leads favorably known health-promoting microorganisms over pathogens or nonbeneficial bacteria. Diet-based interventions such as the low-FODMAP diet, which targets carbohydrate fermentation in IBS symptom management, have been very effective. Consumption of high quantities of plant-based diet fiber similarly facilitates microbial diversity, favoring SCFA synthesis.
What Are the Challenges for MBTs?
-
Regulatory and Safety Issues: Regulatory and safety concerns restrain the study of microbiome-based therapies, especially those involving live organisms, such as fecal microbiota transplantation, next-generation probiotics, and probiotics, given that they also carry a high risk of germ and infection transmission and spreading.
-
Individual Variability: The enormous and vast level of individual variances and diversity in the gut microbiome presents one of the biggest problems in implementing microbiome-based therapeutics. Each person has a different gut microbiome composition, and their variations depend on many factors like lifestyle, usage of drugs, age, geographical condition, genetics, and food. All these uncertainties make it difficult to predict to what extent a particular therapy could succeed in the case of different people.
How Are Microbiome-Based Therapies Regulated in the United States?
MBTs are meant to act like pharmaceuticals, defined as "substances used as agents to treat, mitigate, diagnose, cure, or prevent human disease." The main governing body of the United States Food and Drug Administration (USFDA) regulates MBTs intended for therapeutic use. It includes bacterial consortia, FMT, and bacterial metabolites. However, the FDA does not regulate probiotics, prebiotics, dietary supplements, or diets in that these do not claim therapeutic potential for specific diseases.
An Investigational New Drug (IND) application is necessary for clinical studies of MBTs. This application gives the FDA authorization to test potentially therapeutic items on humans. These trials must follow recognized guidelines for the disease under study and legislation safeguarding human subjects. For instance, FMT for inflammatory bowel disease needs to adhere to the results of conventional clinical trials for that illness.
Conclusion
Therapies based on the microbiome provide a new and interesting approach to treating gastrointestinal or digestive tract disorders. The gut is healed by known MBTs, such as using probiotics and incorporating fecal microbiota transplants, synbiotics, and prebiotics. It also lessens the symptoms in individuals with conditions like IBD, IBS, and CDI. Patients with digestive disorders may have new hope with increasing personalized, targeted, and effective medications and a growing understanding of the gut or digestive tract flora. More research and clinical trial studies are required to fully understand the benefits and how MBTs fit into routine clinical practice.
